determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
Published 2 weeks ago • 252 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
3:40
recommendations for physicians treating pv: selecting between hydroxyurea and interferon
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
1:40
challenges and options for patients with hydroxyurea-resistant pv
-
1:45
deciding which patients with mpns are suitable candidates for interferon-based therapy
-
1:46
current treatment approaches in et and an insight into the surpass-et trial
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
1:42
applying next-generation sequencing in the diagnosis of rare inherited anemias
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
1:52
single-cell and immune sequencing to predict response and resistance to car-t therapy in r/r mm
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
3:10
understanding resistance mutations with covalent and non-covalent btkis
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks
-
2:12
results from a phase i trial of tinostamustine in patients with r/r classical hl
-
2:03
unmet needs in immune thrombocytopenia
-
1:42
dose escalation of ro7283420, a hla-a2-wt1 cd3 t-cell bispecific antibody, in r/r aml
-
1:24
triple-negative myelofibrosis: disease features and outcomes